Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Trial Profile

Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2016

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shanghai Genechem
  • Most Recent Events

    • 04 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top